Vir Biotechnology (NASDAQ: VIR) insider transactions
In the twelve months to 10 November 2026, executives and directors of Vir Biotechnology reported 34 open-market sales of 1,183,003 shares ($8.2m) and 0 open-market purchases, by 9 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 3 November 2026 | de Verneuil Vanina | EVP, General Counsel, Corp Sec | Open-market sale, 10b5-1 plan | −2,407 | $11.10 | 110,193 | Form 4 |
| 2 November 2026 | de Verneuil Vanina | EVP, General Counsel, Corp Sec | Open-market sale, 10b5-1 plan | −1,343 | $11.33 | 112,600 | Form 4 |
| 27 October 2026 | Topalian Suzanne Louise | Director | Grant or award | +8,000 | — | 8,000 | Form 4 |
| 27 October 2026 | Topalian Suzanne Louise | Director | Grant or award | +4,731 | — | 12,731 | Form 4 |
| 11 August 2026 | More Robert J | Director | Other | −8,000 | — | 40,656 | Form 4 |
| 11 August 2026 | More Robert J | Director | Other | +8,000 | — | 517,917 | Form 4 |
| 9 June 2026 | Coughlin Timothy | Director | Grant or award | +8,000 | — | 8,000 | Form 4 |
| 9 June 2026 | Coughlin Timothy | Director | Grant or award | +8,000 | — | 16,000 | Form 4 |
| 1 June 2026 | Sabatini Brent | SVP, Chief Accounting Officer | Open-market sale, 10b5-1 plan | −379 | $9.45 | 61,902 | Form 4 |
| 1 June 2026 | Napolitano Janet | Director | Open-market sale, 10b5-1 plan | −3,200 | $9.45 | 21,216 | Form 4 |
| 27 May 2026 | Bischofberger Norbert W | Director | Grant or award | +8,000 | — | 21,333 | Form 4 |
| 27 May 2026 | Farid Ramy | Director | Grant or award | +8,000 | — | 32,000 | Form 4 |
| 27 May 2026 | Hatfield Jeffrey S. | Director | Grant or award | +8,000 | — | 39,806 | Form 4 |
| 27 May 2026 | More Robert J | Director | Grant or award | +8,000 | — | 48,656 | Form 4 |
| 27 May 2026 | Napolitano Janet | Director | Grant or award | +8,000 | — | 24,416 | Form 4 |
| 27 May 2026 | Sigal Charles Elliott | Director | Grant or award | +8,000 | — | 39,806 | Form 4 |
| 1 May 2026 | Sato Vicki L | Director | Open-market sale, 10b5-1 plan | −22,000 | $10.05 | 1,078,391 | Form 4 |
| 29 April 2026 | De Backer Marianne | President and CEO | Other | −233,532 | — | 714,613 | Form 4 |
| 29 April 2026 | De Backer Marianne | President and CEO | Other | +233,532 | — | 286,650 | Form 4 |
| 6 April 2026 | De Backer Marianne | President and CEO | Open-market sale, 10b5-1 plan | −72,559 | $9.16 | 948,145 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Vir Biotechnology page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.